BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 3143076)

  • 21. Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc.
    Allen JD; Verhoeven E; Domen J; van der Valk M; Berns A
    Oncogene; 1997 Sep; 15(10):1133-41. PubMed ID: 9294606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A p53 defect sensitizes various stages of B cell development to lymphomagenesis in mice carrying an IgH 3' regulatory region-driven c-myc transgene.
    Fiancette R; Rouaud P; Vincent-Fabert C; Laffleur B; Magnone V; Cogné M; Denizot Y
    J Immunol; 2011 Dec; 187(11):5772-82. PubMed ID: 22039300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acceleration of B-lymphoid tumorigenesis in E mu-myc transgenic mice by v-H-ras and v-raf but not v-abl.
    Langdon WY; Harris AW; Cory S
    Oncogene Res; 1989; 4(4):253-8. PubMed ID: 2549487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. B-cell tumorigenesis in mice carrying a yeast artificial chromosome-based immunoglobulin heavy/c-myc translocus is independent of the heavy chain intron enhancer (Emu).
    Palomo C; Zou X; Nicholson IC; Bützler C; Brüggemann M
    Cancer Res; 1999 Nov; 59(21):5625-8. PubMed ID: 10554044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interaction of abl and raf with IL-7 signaling pathway and transformation of pre-B cells from resistant mice.
    Hilbert DM; Theisen PW; Rudikoff EK; Bauer SR
    Oncogene; 1998 Oct; 17(16):2125-35. PubMed ID: 9798684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. N-myc activation by proviral insertion in MCF 247-induced murine T-cell lymphomas.
    Dolcetti R; Rizzo S; Viel A; Maestro R; De Re V; Feriotto G; Boiocchi M
    Oncogene; 1989 Aug; 4(8):1009-14. PubMed ID: 2548143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ig heavy chain protein controls B cell development by regulating germ-line transcription and retargeting V(D)J recombination.
    Schlissel MS; Morrow T
    J Immunol; 1994 Aug; 153(4):1645-57. PubMed ID: 8046237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cooperation of Gata3, c-Myc and Notch in malignant transformation of double positive thymocytes.
    van Hamburg JP; de Bruijn MJ; Dingjan GM; Beverloo HB; Diepstraten H; Ling KW; Hendriks RW
    Mol Immunol; 2008 Jun; 45(11):3085-95. PubMed ID: 18471881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A myeloma translocation-like model associating CCND1 with the immunoglobulin heavy-chain locus 3' enhancers does not promote by itself B-cell malignancies.
    Fiancette R; Amin R; Truffinet V; Vincent-Fabert C; Cogné N; Cogné M; Denizot Y
    Leuk Res; 2010 Aug; 34(8):1043-51. PubMed ID: 20018375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cell populations during tumorigenesis in Eu-myc transgenic mice.
    Sidman CL; Shaffer DJ; Jacobsen K; Vargas SR; Osmond DG
    Leukemia; 1993 Jun; 7(6):887-95. PubMed ID: 8501983
    [TBL] [Abstract][Full Text] [Related]  

  • 31. H-2/myc, E mu/myc, and c-myc transgenic mice: potent sources of early hematopoietic cell lines.
    Roland J; Morello D
    Cell Growth Differ; 1993 Nov; 4(11):891-900. PubMed ID: 8297795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transformation of hemopoietic cells by raf and myc oncogenes: a new perspective on lineage commitment.
    Klinken SP
    Cancer Cells; 1991 Oct; 3(10):373-82. PubMed ID: 1777358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A truncated heavy chain protein relieves the requirement for surrogate light chains in early B cell development.
    Shaffer AL; Schlissel MS
    J Immunol; 1997 Aug; 159(3):1265-75. PubMed ID: 9233622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antisense oligodeoxynucleoside methylphosphonate inhibition of mouse c-myc p65 protein expression in E mu-c-myc transgenic mice.
    Wickstrom E; Bacon TA; Wickstrom EL; Werking CM; Palmiter RD; Brinster RL; Sandgren EP
    Nucleic Acids Symp Ser; 1991; (24):151-4. PubMed ID: 1841270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The functional basis of c-myc and bcl-2 complementation during multistep lymphomagenesis in vivo.
    Marin MC; Hsu B; Stephens LC; Brisbay S; McDonnell TJ
    Exp Cell Res; 1995 Apr; 217(2):240-7. PubMed ID: 7698223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The VpreB1 enhancer drives developmental stage-specific gene expression in vivo.
    Licence S; Persson C; Mundt C; Mårtensson IL
    Eur J Immunol; 2003 Apr; 33(4):1117-26. PubMed ID: 12672078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased transcription of the E mu-myc transgene and mRNA stabilisation produce only a modest elevation in Myc protein.
    Colley SM; Tilbrook PA; Klinken SP
    Oncogene; 1997 Jun; 14(22):2735-9. PubMed ID: 9178772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transgenic mice bearing the human c-myc gene activated by an immunoglobulin enhancer: a pre-B-cell lymphoma model.
    Schmidt EV; Pattengale PK; Weir L; Leder P
    Proc Natl Acad Sci U S A; 1988 Aug; 85(16):6047-51. PubMed ID: 3261863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduction of early B lymphocyte precursors in transgenic mice overexpressing the murine heat-stable antigen.
    Hough MR; Chappel MS; Sauvageau G; Takei F; Kay R; Humphries RK
    J Immunol; 1996 Jan; 156(2):479-88. PubMed ID: 8543797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. B lineage-restricted rearrangement of a human Ig kappa transgene.
    Cavelier P; Nato F; Coquilleau I; Rolink A; Rougeon F; Goodhardt M
    Eur J Immunol; 1997 Jul; 27(7):1626-31. PubMed ID: 9247570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.